Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
Status:
Completed
Trial end date:
2020-04-29
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to
evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in
female subjects 12 years and older with AVVC.